Most private insurance, ACA marketplace plans, Medicare Part D, Medicaid, and VA health care cover Humira or one of its FDA-approved adalimumab biosimilars, but the practical answer to what insurance plans cover Humira has shifted sharply in 2026: the three largest pharmacy benefit managers have dropped brand-name Humira from their standard commercial formularies in favor of biosimilars, and even where brand coverage remains, specialty-tier placement means significant out-of-pocket costs until you hit your plan’s annual cap.
Marketplace and Individual Plans
Plans bought through the ACA marketplace or directly from an insurer generally cover adalimumab products, though brand-name Humira may no longer appear on every formulary. Most marketplace plans classify biologics like Humira as specialty-tier drugs, which carry the highest cost-sharing. Coinsurance for specialty-tier medications on marketplace silver plans averages roughly 30 to 36 percent of the drug’s cost, and some plans charge as much as 50 percent. Applied to a biologic, that adds up fast.
Before coverage kicks in, you typically need to meet your deductible. Silver-plan deductibles often exceed $5,000, and bronze plans approach $7,500. The 2026 ACA out-of-pocket maximum is $10,600 for individual coverage and $21,200 for a family plan, so your total annual spending on covered services is capped at that level regardless of how expensive the medication is. Once you hit that ceiling, the plan pays 100 percent for the rest of the year.
Every marketplace plan publishes a formulary listing which drugs it covers and on which tier, and these change every year. An insurer might carry brand-name Humira one year and replace it with a preferred biosimilar the next, or move it to a less favorable tier. Checking your plan’s formulary during open enrollment is the single most important step you can take to avoid a coverage surprise. Some plans also require you to fill specialty prescriptions through a designated mail-order or specialty pharmacy, which affects delivery timing.
Employer-Sponsored Plans
Employer-based group insurance is how most working-age adults get coverage for high-cost biologics. These plans often negotiate better rates than individual policies because the employer subsidizes premiums and the larger risk pool gives the insurer more leverage with drug manufacturers. Coverage details still depend on how the employer designed the plan.
Large employers tend to offer plans with lower deductibles and more generous drug benefits. Smaller companies more often provide high-deductible health plans that require substantial spending before prescription coverage begins. Either way, Humira or its biosimilars almost always sit on the specialty tier, with coinsurance in the range of 20 to 40 percent rather than a simple flat copay. Some plans cap monthly specialty copays, but the cap varies widely.
If your employer offers a health savings account paired with a high-deductible plan, or a flexible spending account, you can use pre-tax dollars toward Humira costs. That effectively gives you a discount equal to your marginal tax rate on every dollar you set aside. Review your Summary of Benefits and Coverage document and drug formulary each enrollment period, since employer plans change their formulary and tier structure annually.
Medicare Part D
Medicare beneficiaries get prescription drug coverage through standalone Part D plans or Medicare Advantage plans that include drug benefits. Nearly all standalone Part D plans (96 percent) and 88 percent of Medicare Advantage drug plans covered at least one adalimumab biosimilar on their 2025 formulary, and some plans covered biosimilars only, not brand-name Humira.1Office of Inspector General. Most Medicare Part D Plans Formularies Included Humira Biosimilars for 2025
The Inflation Reduction Act’s Part D changes are now fully in effect. The old coverage gap, where beneficiaries paid 25 percent of drug costs between roughly $5,000 and $8,000 in spending, was eliminated starting in 2025. In 2026, once your out-of-pocket prescription costs reach $2,100, you enter catastrophic coverage and pay nothing for covered medications for the rest of the year.2Medicare.gov. Medicare and You Handbook 2026 For a biologic that can cost several thousand dollars a month, that $2,100 annual cap is transformative compared to what Part D enrollees paid two years ago.
Medicare also offers the Medicare Prescription Payment Plan, which lets you spread your out-of-pocket drug costs into capped monthly installments instead of paying them all upfront at the pharmacy. You pay nothing at the counter, and your Part D plan bills you monthly. If any single prescription triggers cost-sharing of $600 or more, your plan must notify you that you may benefit from this option. The annual cap does not change, but the payment structure can make a biologic affordable month-to-month rather than requiring a large lump sum early in the year.
Each Part D plan still has its own formulary, and tier placement for adalimumab products varies. Check your plan’s formulary before enrolling or during the annual enrollment period to confirm which adalimumab product is covered and at what tier.
Medicaid
Medicaid programs generally cover Humira and its biosimilars with minimal out-of-pocket cost. Under federal rules, if a drug manufacturer participates in the Medicaid Drug Rebate Program, state Medicaid programs must cover that manufacturer’s FDA-approved drugs in fee-for-service settings, though states can impose prior authorization requirements.3Federal Register. Medicaid Program – Covered Outpatient Drugs Medicaid managed care plans have somewhat more formulary flexibility but must still ensure enrollees can access covered drugs.
Copays under Medicaid are typically a few dollars or nothing at all, depending on the state and your income. The trade-off is that many state programs use step therapy, meaning you may need to try and fail on a less expensive treatment before the program will approve a biologic. Utilization controls vary by state.
VA Health Care
The Department of Veterans Affairs covers adalimumab, with an important distinction. Brand-name Humira is not on the VA national formulary and requires a non-formulary drug request with prior approval before a VA pharmacy will dispense it.4Department of Veterans Affairs. VA Formulary Advisor – ADALIMUMAB INJ SOLN An adalimumab biosimilar (adalimumab-bwwd) is on the VA national formulary as a Tier 2 medication, though it may still require prior authorization at the local facility level.5Department of Veterans Affairs. VA Formulary Advisor – ADALIMUMAB-BWWD INJ SOLN
The VA negotiates drug prices directly with manufacturers, which results in significantly lower costs than private insurance. For a Tier 2 outpatient medication, the VA copay is $8 for a 30-day supply.6Department of Veterans Affairs. Current VA Health Care Copay Rates Many veterans qualify for copay exemptions based on service-connected disability ratings or income, bringing the cost to zero. If your provider believes you specifically need brand-name Humira rather than the biosimilar, they can submit a non-formulary request, but expect the process to take longer.
The Shift to Biosimilars in 2026
This is the single biggest change affecting Humira coverage, and most patients don’t see it coming until they try to refill their prescription. The three largest pharmacy benefit managers (CVS Caremark, Express Scripts, and Optum Rx) have largely removed brand-name Humira from their standard 2026 commercial formularies in favor of biosimilar alternatives. Express Scripts’ 2026 national preferred formulary, for example, lists several adalimumab biosimilars as preferred while excluding the brand-name product.7Express Scripts. 2026 Express Scripts National Preferred Formulary
Formulary exclusions are recommendations from the PBM to plan sponsors, meaning your employer or insurer, not absolute mandates. Some employers choose not to adopt their PBM’s standard exclusion list, so brand-name Humira may still be available on certain plans even when the PBM’s default formulary drops it. The only way to know is to check your specific plan’s formulary.
FDA-approved adalimumab biosimilars are clinically equivalent to Humira for the same approved uses, and several carry interchangeable designations, meaning a pharmacist can substitute without a new prescription. Your prescriber can still write a prescription as “dispense as written” and block substitution. If your plan only covers a biosimilar and your doctor insists on brand-name Humira, you would likely need to go through prior authorization or an exception process. For most patients, switching to a biosimilar means lower costs with the same clinical results. If your insurer notifies you of a formulary change, talk to your doctor about which covered biosimilar is appropriate rather than assuming you have no options.
Copay Cards and the Accumulator Trap
AbbVie offers a savings card through its HUMIRA Complete program that covers up to $14,000 per calendar year in copay or coinsurance costs for eligible commercially insured patients. The card is not available if you have Medicare, Medicaid, TRICARE, VA coverage, or any other government-funded insurance.8Humira. Ways to Save on HUMIRA (adalimumab) – HUMIRA Complete For commercially insured patients paying coinsurance on a specialty biologic, $14,000 in annual assistance can be the difference between affording the medication and not.
There is a significant catch. Many insurers have adopted copay accumulator adjustment programs, which prevent manufacturer copay card payments from counting toward your annual deductible or out-of-pocket maximum. Your manufacturer card pays your copay for several months, but because those payments don’t count toward your deductible, you eventually exhaust the card’s value and then owe your full deductible on top of ongoing coinsurance. A patient with a $5,000 deductible and a $4,000 copay card could burn through the card without reducing the deductible by a single dollar.
AbbVie’s program states that patients whose plans use accumulator or copay maximizer programs may not be eligible for the full savings benefit, and support may be reduced to no more than $4,000. Roughly half the states plus the District of Columbia have passed laws banning accumulator programs, requiring manufacturer assistance to count toward the patient’s deductible and out-of-pocket maximum. If you live in a state without such a ban, check your plan documents for language about “copay accumulator adjustment” or “maximizer” programs before relying on manufacturer assistance to carry you through the year.
Prior Authorization and Step Therapy
Almost every insurer requires prior authorization before approving Humira or an adalimumab biosimilar. Your doctor submits documentation showing your diagnosis, treatment history, and why the medication is medically necessary. This is where claims stall most often. Incomplete paperwork, missing lab results, or a vague clinical justification will get denied, and then you are starting the process over. Ask your doctor’s office whether they have experience submitting prior authorizations for biologics and confirm they will include all relevant records upfront.
Many plans also impose step therapy, requiring you to try and fail on one or more lower-cost medications before they will approve a biologic. For conditions like rheumatoid arthritis, this often means trying a conventional disease-modifying drug first. Step therapy can delay access by weeks or months. For Medicare Advantage plans, you have the right to request an expedited exception to step therapy requirements, and the plan must respond as quickly as your medical condition requires, generally within 72 hours.9Centers for Medicare and Medicaid Services. Medicare Advantage Prior Authorization and Step Therapy for Part B Drugs For commercial plans, exception processes vary, but your doctor can typically request an override by documenting why the stepped alternatives are medically inappropriate for you.
How to Appeal a Coverage Denial
If your insurer denies coverage for Humira or a biosimilar, you have the right to appeal. The process has two stages, and the federal timelines are more generous than many patients realize.
The first stage is an internal appeal filed with your insurer. You have 180 days from the date you receive the denial notice to file. Include everything that strengthens your case: medical records, a letter of medical necessity from your prescribing doctor, documentation of failed alternative treatments, and clinical evidence supporting the medication for your condition. The insurer must complete its review within 30 days if you are seeking approval for a treatment you have not yet received, or within 60 days for services already provided. For urgent medical situations, the insurer must decide within 72 hours.10HealthCare.gov. Internal Appeals
If the internal appeal fails, you can request an external review by an independent third party with no financial relationship to your insurer. File this request within four months of the final internal denial. Federal law requires all insurance companies to offer an external review process meeting federal consumer protection standards, and the independent reviewer must issue a decision within 45 days for standard cases or 72 hours for urgent medical needs.11HealthCare.gov. External Review If the external reviewer overturns the denial, the insurer must cover the medication as prescribed. External review is the stage where strong documentation pays off most, because the independent reviewer looks at the full medical record without the insurer’s financial incentives influencing the decision.
Keep copies of every document you submit and every response you receive. If the process feels overwhelming, patient advocacy organizations for your specific condition often have staff who help navigate insurance appeals at no cost.